Targeting Myeloid Cells to Shape Tumor
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 3688
Special Issue Editor
Interests: tumor immunology; immunodeficiency; macrophages; dendritic cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Myeloid cells (monocytes, dendritic cells, macrophages, myeloid-derived suppressive cells and neutrophils) in the tumor microenvironment (TME) shape immunity against cancer cells. In the past decade, numerous studies have provided novel insights into the complexity of myeloid subsets and their functional diversity within tumors. Myeloid cells can either promote anti-tumor immunity or contribute to tumor progression depending on the cell population, cell subset and/or their activation status. Particularly, these myeloid cells act as antigen-presenting cells and therefore initiate adaptive immune responses, but they also produce/express diverse molecules to promote tumor progression. Consequently, multiple approaches have recently been developed to target these cells by depleting them, activating them or remodeling their phenotypes in order to restore or boost anti-tumor immune responses.
The Special Issue “Targeting Myeloid Cells to Shape Tumor Immunity” aims to highlight the importance of myeloid cells in tumor immunosurveillance and their targeting as a potential therapeutic approach. Articles or reviews on the following, but not limited to, topics are welcome:
- Heterogeneity of myeloid cells in the TME;
- Phenotypical and functional characteristics of TME-infiltrating myeloid cells;
- Plasticity of myeloid cells;
- Myeloid-cell-mediated modulation of tumor immunity;
- Myeloid cells and responses to immunotherapies;
- Novel approaches to target myeloid cells in tumors.
Dr. Dorothée Duluc
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dendritic cells
- macrophages
- neutrophils
- MDSC
- tumor immunity
- immunotherapies
- TME
